CVD Prevention Market (By Product Types: Detection & Diagnosis [Artificial intelligence in cardiovascular imaging, In vitro diagnostics at point-of-care], Remote Patient Monitoring [Wearable technology for remote patient monitoring, Non-wearable technology for remote patient monitoring], Treatment [Anti-Hypertensives, Anti-Dyslipidemia Drugs, Anti-Thrombotic Drugs]; By End User: Hospital, Home Health Care, Ambulatory Care, Speciality Clinics, Others) - Global Industry Analysis, Market Size, Opportunities and Forecast 2020 - 2027

Category : Healthcare and Pharmaceuticals | Delivery Format : PDF | Status: Published | Pages : 190

The market for CVD Prevention is expected to grow at a CAGR of around 5.8% from 2020 to 2027 and expected to reach the market value of around US$ 258.4 Bn by 2027.

Cardiovascular disease or CVD prevention can be reached by practicing a balanced healthy diet, regular exercise, avoiding smoking, and by the maintenance of optimal blood pressure (BP) and normal LDL-cholesterol and glucose levels. CVD covers a range of different diseases and conditions that affects the heart and/or blood vessels. The most important risk factor of CVD is hypertension and dyslipidemia which accelerates the development of atherosclerotic within blood vessels. Moreover, the treatment of CVD focuses on prevention by controlling the above-mentioned risk factors. The prevention encompasses Anti-hypertensives aims to lower blood pressure, anti-dyslipidemia drugs aim to alter lipid levels to an acceptable range, and anti-thrombotic drugs aim to either prevent thrombus forming or work to mitigate the damage of current thrombi. Along with these, the use of regular monitoring devices is recommended for the prevention of the persons who are at the risk of CVD.

Market Dynamics

The rapidly increasing cases of cardiovascular disease (CVD) across the globe are the alarm that the need for prevention has occurred and the necessary solutions are awaited in the market. According to the World Health Organization (WHO), CVD is responsible for 17 million deaths every year worldwide, which is approximately 31% of total deaths, and expects that this figure will rise to over 23 million by 2030. Additionally, the major economic burden of CVD also favors the growth of the CVD prevention market. For instance, the annual cost of CVD to the economy is estimated to range between £19-35 billion in the UK and over US$500 billion in the US including the cost of health care services, medicines, and loss of productivity due to death. The high prevalence of high blood pressure, high cholesterol, and smoking across the globe are further bolstering the risk of developing CVD. Moreover, the men were more likely than women to have at least one of the three CVD risk factors. Furthermore, ongoing R&D activities and technological advancement are projected to provide potential opportunities over the forecast timeframe from 2020 to 2027.

On the other side, the less frequency of detection and diagnosis of the relevant risk factors due to unawareness among people is likely to restrict the growth to an extent over the estimated period from 2020 to 2027.

North America leading the CVD Prevention market with maximum revenue share

In 2019, North America was leading the global CVD Prevention market with maximum revenue share (%) on account of its increasing geriatric population coupled with the escalating number of CVD patients. According to the U.S. Department of Health & Human Services, around 655,000 Americans die from heart disease every year which is equal to 1 in every 4 deaths. Moreover, Asia Pacific is projected to exhibit the fastest growth with major CAGR (%) throughout the forecast period from 2020 to 2027. The economic development and raising awareness about CVD prevention in the region is supporting the regional market growth.

The players profiled in the report include AstraZeneca plc, Boehringer Ingelheim GmbH, MyoKardia, Novartis, Roche Holding AG., Sanofi S.A., Takeda Pharmaceutical Company Limited, United Therapeutics Corporation, and others. The major CVD prevention players were involved in strategic developments for escalating the profit share in regional as well as the global market. The major investments were announced in the CVD prevention market for technological advancements in the field.

Market Segmentation

Market By Product Types

Detection & Diagnosis

  • Artificial intelligence in cardiovascular imaging
  • In vitro diagnostics at point-of-care

Remote Patient Monitoring

  • Wearable technology for remote patient monitoring
  • Non-wearable technology for remote patient monitoring

Treatment

  • Anti-Hypertensives
  • Anti-Dyslipidemia Drugs
  • Anti-Thrombotic Drugs

Market By End User

Hospital

Home Health Care

Ambulatory Care

Speciality Clinics

Others

Market By Geography

North America

  • U.S.
  • Canada

Europe

  • UK
  • Germany
  • France
  • Spain
  • Rest of Europe

Asia-Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of Middle East & Africa


Frequently Asked Questions

The market for CVD prevention is expected to reach a market value of around US$ 258.4 Bn by 2027.

The CVD prevention market is expected to grow at a CAGR of around 5.8% from 2020 to 2027.

The rapidly increasing cases of cardiovascular disease (CVD) across the globe, need for the prevention, the major economic burden of CVD on countries, and high prevalence of high blood pressure, high cholesterol, and smoking across the globe are some of the factors driving the market growth.

AstraZeneca plc, Boehringer Ingelheim GmbH, MyoKardia, Novartis, Roche Holding AG., Sanofi S.A., Takeda Pharmaceutical Company Limited, United Therapeutics Corporation, and others are the prominent players in the market.

North America held the highest market share in the CVD prevention market.

Asia Pacific is expected to be the fastest growing market over the forecast period.

In end-user segment the hospital segment is growing at faster pace.

Cart Summary


60